Clinical Research Directory
Browse clinical research sites, groups, and studies.
Real-World Treatment Study of Koselugo (Selumetinib)
Sponsor: AstraZeneca
Summary
As part of a post-approval commitment, the Korean health authority requests a study to characterize safety and effectiveness in patients treated with Koselugo (Selumetinib), an oral selective inhibitor of MAPK kinase (MEK) 1 and 2, by physicians in routine clinical practice settings. This study is designed to assess the known safety profile or identify previously unsuspected adverse reactions and evaluate the effectiveness of Koselugo under conditions of routine daily medical practice in Korea. This study will provide information on the Korean patient population that is treated with the study drug.
Key Details
Gender
All
Age Range
3 Years - 99 Years
Study Type
OBSERVATIONAL
Enrollment
200
Start Date
2024-06-15
Completion Date
2031-09-30
Last Updated
2026-03-31
Healthy Volunteers
No
Locations (12)
Research Site
Busan, South Korea
Research Site
Chungcheongbuk-do, South Korea
Research Site
Daejeon, South Korea
Research Site
Gyeonggi-do, South Korea
Research Site
Incheon, South Korea
Research Site
Jeonnam, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Wŏnju, South Korea
Research Site
Yangsan, South Korea